Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Booyuujing
- Development stage
- Unknown
- Lead developer
- Boan Biotech
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Ophthalmic
01
Overview
Booyuujing (BA6101) is a biosimilar recombinant fusion protein developed by Shandong Boan Biotechnology Co., Ltd. It is a biosimilar to aflibercept (Eylea), acting as a vascular endothelial growth factor (VEGF) trap. The molecule consists of the extracellular domains of human VEGF receptors 1 and 2 fused to the Fc portion of human IgG1. By binding to VEGF-A, VEGF-B, and placental growth factor (PlGF), Booyuujing inhibits the activation of VEGF receptors, thereby suppressing pathological angiogenesis and vascular permeability in the retina. It is approved in China for the treatment of various retinal vascular diseases, including wet age-related macular degeneration (wAMD), diabetic macular edema (DME), retinal vein occlusion (RVO), diabetic retinopathy (DR), myopic choroidal neovascularization (mCNV), and retinopathy of prematurity (ROP).
- Brand names
- BooyuujingBoyoujing
- Other names
- aflibercept biosimilarBA6101BA-6101BA 6101
02
Targets
VEGFB (Vascular endothelial growth factor B)VEGFA (Vascular endothelial growth factor A)PGF (Placental Growth Factor)
Beyond the preview
Go deeper on Booyuujing.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Booyuujing.